Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and UnitedHealth (UNH – Research Report) with bullish sentiments.

Insmed (INSM)

In a report released today, Jason Zemansky from Bank of America Securities assigned a Buy rating to Insmed, with a price target of $40.00. The company’s shares closed last Tuesday at $26.47.

According to TipRanks.com, Zemansky is a 4-star analyst with an average return of 19.7% and a 62.8% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Reneo Pharmaceuticals, and Arcus Biosciences.

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $46.33, implying a 72.4% upside from current levels. In a report issued on April 1, Wells Fargo also maintained a Buy rating on the stock with a $55.00 price target.

See the top stocks recommended by analysts >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INSM:

• Insmed price target raised to $40 from $37 at Barclays
• Insmed added to ‘Q2 Tactical Ideas List’ at Wells Fargo
• Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
• Insmed price target raised to $54 from $52 at Guggenheim
• Insmed initiated with a Buy at UBS